Pecavaptan - Bayer
Alternative Names: BAY-1753011Latest Information Update: 05 Nov 2023
At a glance
- Originator Bayer
- Class Chlorobenzenes; Fluorocarbons; Heart failure therapies; Small molecules; Triazoles
- Mechanism of Action Diuretics; Vasopressin 1a receptor antagonists; Vasopressin V2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Heart failure
Most Recent Events
- 01 Mar 2022 Discontinued - Phase-II for Heart failure (Combination therapy, Treatment-experienced) in Austria (PO) due to scientific reason (Bayer Half-Year Financial Report, Page 20)
- 01 Mar 2022 Discontinued - Phase-II for Heart failure (Combination therapy, Treatment-experienced) in Bulgaria (PO) due to scientific reason (Bayer Half-Year Financial Report, Page 20)
- 01 Mar 2022 Discontinued - Phase-II for Heart failure (Combination therapy, Treatment-experienced) in Germany (PO) due to scientific reason (Bayer Half-Year Financial Report, Page 20)